IBRX News - Candlesense

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchor...

How does ImmunityBio’s BioShield™ platform and ANKTIVA pipeline differentiate from competitor efforts in long COVID, and what could that mean for the company's competitive positioning? What is the estimated market size and revenue upside if ANKTIVA receives approval for long COVID, and how does that compare to existing treatment options? How will the upcoming Phase 2 results timeline and potential outcomes influence IBRX's short‑term stock price and volatility?

Clinical trials

5 days ago

Read more businesswire

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete...

How sensitive is ImmunityBio's valuation to future clinical trial outcomes and potential dilution from upcoming financing rounds? Could this early success trigger partnership or licensing interest from larger pharmaceutical companies? What is the competitive landscape for CAR‑NK therapies targeting CD19 and how might ImmunityBio's first‑in‑class status affect its market positioning?

Clinical trials

11 days ago

Read more businesswire

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in...

What are the potential risks if the VA treatment does not translate into broader commercial uptake? How could this development affect the stock's short‑term volatility and trading volume? Will the VA hospital rollout lead to additional procurement contracts or reimbursement advantages for ImmunityBio?

Clinical trials

13 days ago

Read more businesswire

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and six months ended June 30, 2...

Are there any forward‑looking guidance updates or product pipeline milestones that could drive further price movement? What are the anticipated cash flow implications of the current growth trajectory for the company's balance sheet and liquidity position? How does ImmunityBio's Q2 net income and cash burn compare to its peers in the oncology immunotherapy space?

Earnings

19 days ago

Read more businesswire